Back to top

Analyst Blog

Celgene Corporation (CELG - Analyst Report) recently announced that the US Food and Drug Administration (FDA) will review the supplemental New Drug Application (sNDA) for cancer drug Abraxane on a priority basis.

We note that Abraxane is already available in many countries for the metastatic breast cancer indication. In Oct 2012, the FDA approved Abraxane as a first-line combination therapy for treating patients suffering from locally advanced or metastatic non-small cell lung cancer. Celgene is now seeking approval of Abraxane in combination with Eli Lilly and Company’s (LLY - Analyst Report) Gemzar as a first-line therapy in patients suffering from advanced pancreatic cancer.

The sNDA was filed by Celgene in Mar 2013 on the basis of encouraging data from a phase III study (MPACT: n=861), which evaluated the combination of Abraxane and Gemzar in the indication. A response from the FDA is expected to be out by Sep 21, 2013 (target date).

We note that the US regulatory authority generally reviews those drugs on a priority basis which offer major advances in treating diseases having no adequate therapy. Applications for priority review designated drugs are reviewed by the FDA within six months of submission.

We note that Abraxane in combination with Gemzar is also under review in the EU for the advanced pancreatic cancer indication. Celgene intends to seek Abraxane approval for the new indication in other countries during the course of the year. Approval for the additional indication would boost Abraxane’s sales potential significantly.

Celgene, a biopharmaceutical company, currently carries a Zacks Rank #2 (Buy). Alexion Pharmaceuticals, Inc. (ALXN - Analyst Report) and Cubist Pharmaceuticals, Inc. (CBST - Analyst Report) look equally attractive in the biopharma space with a Zacks Rank #2 each.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%